The Bang For Celgene’s Buck: Looking Inside The Record-Setting Juno Deal
Celgene’s $1 billion collaboration with Juno was the highest ever upfront payment for a biopharma licensing deal. Execs broke down the deal specifics in an interview with “The Pink Sheet.”
You may also be interested in...
Regeneron will make a $100m equity investment in bluebird to collaborate on the discovery of antibodies and T cell receptors, with the hope of building out in immuno-oncology and overcoming some of the early cell therapy challenges. Regeneron's business development chief talks to Scrip about its strategy.
Bristol paid a handsome $1.85bn upfront for access to Nektar's lead immuno-oncology program NKTR-214 to study in combination with its own drugs, but the expense was viewed by some as a smart play versus buying Nektar outright.
Data from a Phase I trial testing the CAR-T therapy bb2121 in in heavily treated patients with relapsed refractory multiple myeloma were encouraging, driving bluebird's stock up 10%.